Risk Factors for the First Episode of Klebsiella pneumoniae Resistant to Carbapenems Infection in Critically Ill Patients: A Prospective Study

Table 5

Characteristics of survivors and nonsurvivors in the ICU.

	Survivors; (𝑁=49)	Nonsurvivors; (𝑁=33)	𝑃
Sex (male)	31 (63.3)	23 (69.7)	0.638
Age (years)	55 (36, 37)	62 (52, 73)	0.023
Medical patients	18 (36.7)	21 (63.6)	0.024
APACHE II score	14 (10, 19)	15 (13, 18)	0.710
SOFA score	7 (5–8)	7 (5, 9)	0.121
Diabetes mellitus	3 (6.1)	6 (18.8)	0.144
Chronic lung disease	5 (10.2)	6 (18.8)	0.328
Chronic heart disease	15 (30.6)	10 (31.1)	0.571
Other comorbidities	25 (51)	14 (42)	0.546
Immunodeficiency	1 (2)	5 (15.6)	0.033
Invasive procedures	2 (4.1)	7 (21.2)	0.027
Appropriate empirical antibiotic treatment	14 (70)	17 (73.9)	0.521
Appropriate definitive antibiotic treatment	19 (95)	22 (95.7)	0.720
Total ICU duration (days)	12 (7, 23)	14 (9, 28)	0.230
MV total duration (days)	9 (4, 16)	14 (9–28)	0.007
Sedation total duration (days)	4 (2, 10)	9 (5, 15)	0.009
KPRC infection	10 (20.4)	15 (45.5)	0.027

Data are presented as median (25% and 75% quartiles) or 𝑛 (%); KPRC: Klebsiella pneumonia resistant to carbapenems; other comorbidities included hematological disease, chronic kidney and chronic liver disease; appropriate empirical antimicrobial treatment, administration of in vitro active antimicrobials against the study isolates within 24 h from infection onset; appropriate definitive antibiotic treatment, administration of in vitro active antibiotics for at least 48 h; ICU: Intensive Care Unit; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; MV: mechanical ventilation; Results are by univariate analysis.